Abstract 94P
Background
Mean platelet volume (MPV) is a marker of inflammation that indicates the average size of platelets, platelet production rate and stimulation. The role of Pre-operative levels of MPV and its prognostic effect on disease free survival (DFS) and overall survival (OS) are poorly understood. This study was intended to analyze the effect of pre-operative levels of MPV on DFS and OS of stage III rectal cancer patients.
Methods
This is a retrospective study of 149 stage III rectal cancer patients who underwent surgery in our institution between 2011 and 2015. Association between pre-operative levels of MPV and clinicopathological variables were analysed. DFS and OS for 5 years were analysed, and survival analysis was done using Kaplan-Meier curve. MPV of 9.35 femto litres (fl) was chosen based on the ROC curve. The Area under curve was 0.889. Differences between survival curves were analysed for statistical significance using log-rank test.
Results
In our study, mean 5-year OS were 91.1 and 50.36 months, for patients with MPV < 9.35 and MPV >9.35 respectively (P 0.0001). The mean DFS of MPV < 9.35 and MPV > 9.35 were 89.32 and 43.54 months respectively (P 0.0001). Univariate analysis for OS and DFS showed significance for MPV, Nodal status, Circumferential resection margin, stage and lymph node ratio. Multivariate analysis showed significance for MPV [HR 2.379 (95% CI 1.733-3.264) P .0001 for MPV>9.35] and CRM [HR 0.392 (95% CI 0.191-0.804) P 0.01) for CRM negative] for OS and DFS. Multivariate Analysis for OS & DFS Table: 94P
Variable | OS | DFS | ||||||
P value | Hazard Ratio | 95% CI | P value | Hazard Ratio | 95% CI | |||
Lower | Upper | Lower | Upper | |||||
N Stage | ||||||||
N1a | .782 | .785 | .140 | 4.390 | .824 | .833 | .167 | 4.146 |
N1b | .119 | .322 | .077 | 1.340 | .159 | .389 | .104 | 1.448 |
N2a | .554 | .715 | .235 | 2.175 | .680 | .810 | .297 | 2.209 |
N2b | Reference | Reference | ||||||
CRM | ||||||||
Negative | .011 | .392 | .191 | .804 | .012 | .412 | .207 | .821 |
Positive | Reference | Reference | ||||||
Stage | ||||||||
IIIA | .568 | .692 | .196 | 2.447 | .203 | .465 | .143 | 1.510 |
IIIB | .474 | .727 | .303 | 1.743 | .203 | .607 | .281 | 1.310 |
IIIC | Reference | Reference | ||||||
MPV | ||||||||
>9.35 | .0001 | 2.379 | 1.733 | 3.264 | .0001 | 2.370 | 1.791 | 3.136 |
<9.35 | Reference | Reference | ||||||
LNR ratio | ||||||||
>0.2 | .220 | 3.269 | .492 | 21.738 | .059 | 5.756 | .938 | 35.327 |
<0.2 | Reference | Reference |
Conclusions
Pre-operative MPV measured one week before surgery is a convenient and inexpensive marker which has been proved to be a prognostic marker for OS and DFS in stage III rectal cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kidwai Memorial Institute of Oncology, Bangalore, India.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session